Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Marth, ChristianTarnawski, RafalTyulyandina, AlexandraPignata, SandroGilbert, LucyKaen, DiegoRubio, M. JesusFrentzas, SophiaBeiner, MarioMagallanes-Maciel, ManuelFarrelly, LauraChoi, Chel HunBerger, ReginaLee, ChristineVulsteke, ChristofHasegawa, KoseiBraicu, Elena IoannaWu, XiaohuaMcKenzie, JodiLee, John J.Makker, Vicky2025-01-072025-01-072021-11-181048-891Xhttps://hdl.handle.net/10668/25441Background Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) afterenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001research article34799418open access10.1136/ijgc-2021-0030171525-1438https://ijgc.bmj.com/content/ijgc/32/1/93.full.pdf722241300001